In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Biodesix expects to deliver $106 million to $112 million in annual revenue for 2026, representing 23% growth at the midpoint over 2025. The guidance includes consideration of recent weather events and ...

Friday, February 20, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip ...

世界の遺伝子増幅技術市場は、2024年から2032年にかけて、286億米ドルから374億米ドルまでの収益増加が見込まれ、年平均成長率（CAGR）は3％に達すると予測されています。この市場の成長は、遺伝子増幅技術が医療診断、研究、およびバイオテクノロジー分野での応用の増加に伴い、ますます重要性を増していることに起因しています。本記事では、遺伝子増幅技術の概要、用途、成長を支える要因について詳細に解説 ...

世界のラテラルフローアッセイ（LFA）市場は、2023年の95億1,880万米ドルから2032年までに141億4,590万米ドルに達すると予測されており、2024年から2032年にかけて年平均成長率（CAGR）4.5％で安定した成長が見込まれています ...

Here are some hints to help you win NYT Connections #983.

This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

Human MAP1LC3B (LC3B) binds proteins involved in autophagy and other cellular processes using a degenerate four-residue short linear motif known as the LC3-interacting region (LIR). Biochemical and ...

Agreement integrates Clyde Biosciences' human-relevant, CellOPTIQ cardiotoxicity screen for chemical safety assessment ...